(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 January 2011 (27.01.2011)

PCT

(10) International Publication Number
WO 2011/010969 A1

(51) International Patent Classification:
G01N 33/52 (2006.01) *G01N 33/574* (2006.01)

(21) International Application Number:
PCT/SG2010/000280

(22) International Filing Date:
23 July 2010 (23.07.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
200904976-8 23 July 2009 (23.07.2009) SG

(71) Applicant *(for all designated States except US)*: **NATIONAL UNIVERSITY OF SINGAPORE** [SG/SG]; 10 Kent Ridge Crescent, Singapore 119260 (SG).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **LIM, Yoon Pin** [SG/SG]; c/o Oncology Research Institute, Centre for Life Sciences, 28 Medical Drive #02-14C, Singapore 117456 (SG).

(74) Agent: **YU SARN AUDREY & PARTNERS**; 24 Raffles Place, #27-01, Clifford Centre, Singapore 048621 (SG).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*


Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: CANCER BIOMARKER AND THE USE THEREOF

Figure 5E



(57) Abstract: Gastric cancer is one of the leading causes of cancer-related death worldwide. To date no specific marker is available for gastric cancer screening. The expression profile of 37 proteins was identified to be consistently different between the plasma of normal and gastric cancer subjects. The expression of complement component C9 protein was validated to be significantly higher in the plasma of gastric cancer compared to normal subjects. This was independent of the gastritis and H. pylori status of the patients. We also observed a statistically significant difference ($p<0.04$) in the expression level of C9 between patients with intestinal and diffuse types of cancer. Two independent blind test studies showed a high sensitivity and specificity to detect gastric cancer. The C9 protein is a biomarker for screening gastric cancer.

WO 2011/010969 A1